DOP 108

DOP 108 is a novel small-molecule ligand of the delta opioid receptor (DOR), rationally designed as a derivative of the selective DOR antagonist naltrindole. Developed by researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ), DOP 108 has demonstrated the ability to inhibit the proliferation of human U266 multiple myeloma cells in vitro. While it binds to the delta opioid receptor, its anti-proliferative effects in multiple myeloma are hypothesized to involve interaction with a non-opioid receptor target, similar to its parent compound naltrindole. It was identified alongside other analogs such as DOP 121, DOP 126, and DOP 402.